Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with


ASCO Abstract #
Tepotinib (MET kinase inhibitor): 9005

Not intended for UK- , Canada- or US-based media

DARMSTADT, Germany, June 3, 2019 /PRNewswire/ —

— Alterations of the MET signaling pathway are present in 3-5% of
non-small cell lung cancer patients and correlate with poor prognosis
— New interim data from Phase II VISION study (all lines of treatment)
show tepotinib induced objective responses, as assessed by independent
review, in 50.0% of patients identified by liquid biopsy (LBx) and 45.1%
of patients identified by tissue biopsy (TBx)
— Median duration of response was 12.4 months for LBx-identified patients
and 15.7 months for TBx-identified patients
— Safety results for tepotinib are consistent with those reported in
previous studies; most treatment-related adverse events (TRAEs) were
Grade 1 and 2, and no Grade 4 or 5 TRAEs were observed
Merck, a leading science and technology company, today presented updated results from the potentially registrational Phase II VISION study, showing durable anti-tumor clinical activity for the investigational targeted therapy tepotinib* across different lines of treatment in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping mutations detected by liquid biopsy (LBx) or tissue biopsy (TBx). Data were shared in an oral presentation today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, US.

“Tepotinib has been designed to potentially improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations,” said Luciano Rossetti, Global Head of Research & Development for the Biopharma business of Merck. “Tepotinib is an important part of our strategic focus on precision medicine, and both the proportion of patients responding and the duration of anti-tumor clinical activity demonstrate the potential of this investigational therapy.”

Discovered in-house at Merck, tepotinib is an investigational, highly potent and selective(1) oral MET kinase inhibitor that is designed to inhibit the oncogenic signaling caused by MET (gene) alterations, including both MET exon 14 skipping mutations and MET amplifications, or MET protein overexpression. Alterations of the MET signaling pathway are found in various cancer types, including 3-5% of NSCLC cases, and correlate with aggressive tumor behavior and poor clinical prognosis.(2-4)

“Patients with this NSCLC molecular subtype lack treatment options that have the potential to significantly improve clinical outcomes,” said Paul K. Paik, M.D., primary study investigator and Clinical Director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center. “It is noteworthy to see data that are consistent with tepotinib’s previously reported efficacy findings in this patient population, and that also provide valuable new insight into its durable clinical activity across various treatment lines.”

Results from the ongoing Phase II VISION study in 73 efficacy-evaluable patients with NSCLC with MET exon 14 skipping mutations identified by LBx or TBx demonstrate overall objective response rate (ORR) of 50.0% for LBx-identified patients as assessed by Independent Review Committee (IRC), and 55.3% as assessed by investigators. The ORR for TBx-identified patients was 45.1% and 54.9%, respectively. The overall median duration of response (DOR) was 12.4 months and 17.1 months among LBx-identified patients, as assessed by IRC and investigators, respectively, while among TBx-identified patients, 15.7 and 14.3 months were observed, respectively.

Most treatment-related adverse events (TRAEs) were Grade 1 and 2. No Grade 4 or 5 TRAEs were observed. Any grade TRAEs reported by >=10% of 87 patients evaluable for safety were peripheral edema (48.3%), nausea (23.0%) diarrhea (20.7%) and increased blood creatinine (12.6%). Other relevant TRAEs of any grade include increased lipase (4.6%), fatigue (3.4%) and vomiting (3.4%). TRAEs led to permanent discontinuation in four patients (two patients due to peripheral edema, one due to interstitial lung disease, one due to diarrhea and nausea).

The use of both liquid and tissue biopsies to identify patients for the VISION trial is intended to support improved patient selection and is consistent with the company’s focus on patient-centric drug development.

Tepotinib is currently being investigated in NSCLC in two different settings: in NSCLC harboring MET alterations (MET exon 14 skipping mutations and MET amplifications) as monotherapy, as well as in combination with the tyrosine kinase inhibitor (TKI) osimertinib in epidermal growth factor receptor (EGFR) mutated MET amplified NSCLC having acquired resistance to prior EGFR TKI. Additional information on these clinical trials can be found at ClinicalTrials.gov using the identifiers NCT02864992 and NCT03940703, respectively. Merck is also actively assessing the potential of investigating tepotinib in combination with novel therapies for other tumor indications.

(*)Tepotinib is the recommended International Nonproprietary Name (INN) for the MET kinase inhibitor (MSC2156119J). Tepotinib is currently under clinical investigation and not approved for any use anywhere in the world.

Notes to Editors
Tepotinib oral session:

Title Lead Author Abstract #

Presentation Location
Date / Time
(
CDT
)

Tepotinib

Oral Session

Phase II study of
P.K. Paik 9005
Mon, Jun 3, 8:00
Hall B1
tepotinib in
NSCLC patients with
AM – 11:00 AM
(9:24 AM – 9:36

METex14 mutations AM lecture time)

— —

About Non-Small Cell Lung Cancer
With 2 million cases diagnosed annually, lung cancer (including trachea, bronchus, and lung) is the most common type of cancer worldwide, and the leading cause of cancer-related death, with 1.7 million mortality cases worldwide.(5) Alterations of the MET signaling pathway, including MET exon 14 skipping mutations and MET amplifications, occur in 3-5% of NSCLC cases.(2-4)

About Tepotinib
Tepotinib, discovered in-house at Merck, is an investigational oral MET inhibitor that is designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations, including both MET exon 14 skipping mutations and MET amplifications, or MET protein overexpression. It has been designed to have a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.

Tepotinib is currently being investigated in NSCLC and Merck is actively assessing the potential of investigating tepotinib in combination with novel therapies and in other tumor indications.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe [http://www.merckgroup.com/subscribe] to register online, change your selection or discontinue this service.

About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck generated sales of EUR 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

References

1. Bladt, F et al. Clin Cancer Res 2013;19:2941-2951.
2. Reungwetwattana T, et al. Lung Cancer 2017;103:27-37.
3. Mo HN, et al. Chronic Dis Transl Med 2017; 3(3):148-153.
4. Lutterbach B, et al. Cancer Res 2007;67:2081-8.
5. Bray F, et al. CA Cancer J Clin. Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in 185
countries. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
PMID:30207593

Logo: https://mma.prnewswire.com/media/765882/Merck_Logo.jpg [https://mma.prnewswire.com/media/765882/Merck_Logo.jpg]

https://mma.prnewswire.com/media/765882/Merck_Logo.jpg [https://mma.prnewswire.com/media/765882/Merck_Logo.jpg]

CONTACT: Brenda.Mulligan@merckgroup.com, Phone: +1 978 821 5345

BizPress.nl